Abstract: The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.
Type:
Grant
Filed:
August 11, 2009
Date of Patent:
November 4, 2014
Assignee:
Sanofi Pasteur Biologics, LLC
Inventors:
Simon Delagrave, Rachid Oubelaid, John Hamberger
Abstract: Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.
Type:
Grant
Filed:
May 10, 2012
Date of Patent:
October 21, 2014
Assignee:
Genelux Corporation
Inventors:
Aladar A. Szalay, Nanhai Chen, Yong A. Yu, Qian Zhang
Abstract: Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.
Type:
Grant
Filed:
February 23, 2010
Date of Patent:
October 7, 2014
Assignee:
Genelux Corporation
Inventors:
Aladar A. Szalay, Nanhai Chen, Yong A. Yu, Qian Zhang
Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
Type:
Grant
Filed:
December 17, 2012
Date of Patent:
October 7, 2014
Assignee:
AiCuris GmbH & Co. KG
Inventors:
Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.
Type:
Grant
Filed:
July 26, 2012
Date of Patent:
September 30, 2014
Assignee:
Board of Regents, The University of Texas System
Inventors:
Renata Pasqualini, Wadih Arap, Mikhail G. Kolonin
Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.
Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
September 23, 2014
Assignee:
Takeda Vaccines, Inc.
Inventors:
Charles Richardson, Robert F. Bargatze, Joel Haynes, Bryan Steadman
Abstract: A lytic virus specific for a target strain of a microorganism and substantially free of undesirable genes may be utilized in processes including control of populations of microorganisms. The virus may include a host-range mutant, or “h-mutant.” A method for generating virus includes growing virus-resistant variants of a target strain of a microorganism in the presence of viruses that are specific for the target strain. Only h-mutant viruses will proliferate. Wild-type virus-resistant and virus-resistant variants of a microorganism are also disclosed, as are methods generating such variants. Methods for controlling target strain microorganisms include introducing virus into a treatment site where control of a population of a target strain microorganism is desired or introducing virus-resistant variants of a microorganism into treatment sites where the presence of the microorganism is desired.
Abstract: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.
Abstract: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.
Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
Type:
Grant
Filed:
April 18, 2008
Date of Patent:
August 5, 2014
Assignee:
Eli Lilly and Company
Inventors:
Limin Li, Michael Kinch, Michael Goldbiatt
Abstract: The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluorouracil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents.
Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.
Type:
Grant
Filed:
June 26, 2012
Date of Patent:
July 8, 2014
Assignee:
Iowa State University Research Foundation, Inc.
Abstract: The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella typhimurium, Salmonella gallinarum, or Salmonella pullorum, a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella typhimurium, Fowl typhoid caused by Salmonella gallinarum, and Pullorum disease caused by Salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient. The present invention also provides important insights into prevention and control strategies against Salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of Salmonella infection in poultry.
Type:
Grant
Filed:
September 17, 2012
Date of Patent:
July 8, 2014
Assignee:
CJ Cheiljedang Corporation
Inventors:
In Hye Kang, Min Tae Park, Young Wook Cho, Soo An Shin, Hyang Choi
Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
July 1, 2014
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
Abstract: The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2).
Type:
Grant
Filed:
February 8, 2010
Date of Patent:
July 1, 2014
Assignee:
Mymetics Corporation
Inventors:
Sylvain Fleury, Nicolas Mouz, Marie-Gaelle Roger
Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
July 1, 2014
Assignee:
PsiOxus Therapeutics Limited
Inventors:
Paul Harden, Terry Hermiston, Irene Kuhn
Abstract: A method and device to detect Hepatitis C (HCV) antibodies in oral fluid is provided. This method introduces a non-antibody detection molecule that labels all classes of patient antibodies in oral fluid, followed by the specific concentration of labeled anti-HCV antibodies by selective capture in a trapping zone consisting of peptide antigens derived from the HCV genome. Signal generated by the labeled antibodies present in the trapping zone is proportional to the number of anti-HCV antibodies bound to the antigens present in the trapping zone. Presence of signal derived from the capture of antibody/detection molecule complexes in the trapping zone is indicative of past exposure to HCV.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
July 1, 2014
Assignee:
Instant Medical Diagnostics, LLC
Inventors:
Jonathan Zmuda, Lance A. Liotta, Gordon Whiteley
Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
Type:
Grant
Filed:
August 12, 2011
Date of Patent:
June 17, 2014
Assignee:
Novartis AG
Inventors:
Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
Abstract: The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivity against a variety of influenza strains.
Type:
Grant
Filed:
April 29, 2010
Date of Patent:
June 17, 2014
Inventors:
Runtao He, Xuguang Li, Gary Van Domselaar